

Drug Monograph

Drug/Drug **Lidocaine 3% and hydrocortisone 2.5% gel kit /**
Class: **anesthetic and anti-inflammatory**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each gram of this gel contains 30 mg lidocaine hydrochloride and 25 mg of hydrocortisone acetate. The kit contains twenty 7 gram tubes and also contains applicators and moist wipes.

Manufacturer: Seton Pharmaceuticals, Manasquan, NJ 08736

Indications: Lidocaine 3% - Hydrocortisone 2.5% Gel Kit is indicated for the anti-inflammatory and anesthetic relief of itching, pain, soreness, and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.

Costs: Pricing was unavailable at the time of publication.

Summary of Findings: The Division recommends continued prior authorization status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications Under Solicitation

Prepared By: Kathleen Wilbers, Pharm.D.
Date: February 7, 2013